These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 24889748)

  • 41. Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
    Garcia DA
    Thromb Res; 2012 Jan; 129(1):9-16. PubMed ID: 22018997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.
    Overvad TF; Larsen TB; Albertsen IE; Rasmussen LH; Lip GY
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1619-29. PubMed ID: 24215192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
    Martínez-Rubio A; Dan GA; Kaski JC
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ineligibility for anticoagulation in patients with atrial fibrillation.
    del Conde I; Halperin JL
    Am J Med; 2013 Feb; 126(2):105-11. PubMed ID: 23331435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation.
    Lip GY
    Am J Med; 2011 Feb; 124(2):111-4. PubMed ID: 20887966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prevention of stroke in patients with atrial fibrillation and chronic kidney disease: difficult choices and clinical decisions].
    Gorczyca-Michta I; Kluk M; Wożakowska-Kapłon B
    Kardiol Pol; 2012; 70(9):948-52. PubMed ID: 22993008
    [No Abstract]   [Full Text] [Related]  

  • 47. Anticoagulation in chronic kidney disease patients with atrial fibrillation: old vs new drugs.
    Jędras M; Dębowska M; Staszków M
    Wiad Lek; 2019; 72(11 cz 2):2214-2217. PubMed ID: 31860839
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
    Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
    Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Which drug should we use for stroke prevention in atrial fibrillation?
    Lau YC; Lip GY
    Curr Opin Cardiol; 2014 Jul; 29(4):293-300. PubMed ID: 25029448
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation.
    Zoppellaro G; Granziera S; Padayattil Jose S; Denas G; Bracco A; Iliceto S; Pengo V
    Expert Opin Drug Saf; 2015 May; 14(5):683-95. PubMed ID: 25803739
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
    Darius H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
    Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
    Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Study confirms rivaroxaban favorable safety profile].
    Vetter C
    MMW Fortschr Med; 2016 Mar; 158(6):79. PubMed ID: 27084173
    [No Abstract]   [Full Text] [Related]  

  • 57. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation.
    Dhaese SAM; De Vriese AS
    Mayo Clin Proc; 2023 May; 98(5):750-770. PubMed ID: 37028979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.